Altered sumoylation of p63α contributes to the split-hand/foot malformation phenotype

Cell Cycle

Volumn 3, Issue 12, 2004, Pages 1587-1596

  Huang, Yi Ping ^a   Wu, Guojun ^a   Guo, Zhongmin ^a   Osada, Motonobu ^a   Fomenkov, Tanya ^a   Park, Hannah Lui ^a   Trink, Barry ^a   Sidransky, David ^a   Fomenkov, Alexey ^a   Ratovitski, Edward A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MINT; p63; RUNX2; SHFM; Split hand foot malformation; SUMO 1; Ubiquitin

Indexed keywords

PROTEIN; PROTEIN MINT; PROTEIN P63 ALPHA; PROTEIN UBC9; SUMO 1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MESSENGER RNA; PHOSPHOPROTEIN; TP73L PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN CONJUGATING ENZYME UBC9; UBIQUITIN-CONJUGATING ENZYME UBC9;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONJUGATION; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMB MALFORMATION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SPLIT HAND FOOT MALFORMATION; TOOTH DEVELOPMENT; TRANSCRIPTION REGULATION; YEAST; AMINO ACID SEQUENCE; ANIMAL; CELL NUCLEUS; CHEMISTRY; CYTOLOGY; FIBROBLAST; FOOT MALFORMATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HAND MALFORMATION; HELA CELL; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN BINDING; PROTEIN PROCESSING; PROTEIN TRANSPORT; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; CELL NUCLEUS; DNA-BINDING PROTEINS; FIBROBLASTS; FOOT DEFORMITIES, CONGENITAL; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HAND DEFORMITIES, CONGENITAL; HELA CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RNA, MESSENGER; SUMO-1 PROTEIN; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 20244362375     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.12.1290     Document Type: Article

References (73)

1. Duijf P, van Bokhoven H, Brunner H. Pathogenesis of split-hand/split-foot malformation. Hum Mol Genet 2003; 2:R51-60.
2. Brunner H, Hamel B, van Bokhoven H. P63 gene mutations and human developmental syndromes. Am J Med Genet 2002; 112:284-290.
3. Mills A, Zheng B, Wang X, Vogel H, Roop D, Bradley A. P63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-713.
4. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 199; 398:714-8.
5. Koster M, Kim S, Mills A, DeMayo F, Roop D. P63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004; 2:126-131.
6. Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C, Tanaka T, Imai K, Nakamura Y, Tokino T. The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 2002; 277:719-24.
7. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995-1005.
8. Bakkers J, Hild M, Kramer C, Furutani-Seiki M, Hammerschmidt M. Zebcafish DeltaNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. Dev Cell 2002; 2:617-627.
9. Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell 2002; 2:607-166.
10. Heymer J, Ruther U. Syndactyly of Ft/+ mice correlates with an imbalance in bmp4 and fgf8 expression. Mech Dev 1999; 88:173-181.
11. McGcath JA, Duijf PH, Doetsch V, Irvine AD, de Waal R, Vanmolkot KR, Wessagowit V, Kelly A, Atherton DJ, Griffiths WA, Orlow SJ, van Haeringen A, Ausems MG, Yang A, McKeon F, Bamshad MA, Brunner HG, Hamel BC, van Bokhoven H. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 2001; 10:221-9.
12. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99:143-53.
13. van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Guccieri F, Duijf PH, Vanmolkot KR, van Beusekom E, van Beersum SE, Celli J, Merkx GF, Tenconi R, Fryns JP, Verloes A, Newbury-Ecob RA, Raas-Rotschild A, Majewski F, Beemer FA, Janecke A, Chitayat D, Crisponi G, Kayserili H, Yates JR, Neri G, Brunner HG. p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. Am J Hum Genet 2001; 69:481-92
14. Ianakiev P, Kilpatrick MW, Toudjarska I, Basel D, Beighton P, Tsipouras P. Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. Am J Hum Genet 2000; 1:59-166.
15. Sifakis S, Basel D, Ianakiev P, Kilpatrick M, Tsipouras P. Distal limb malformations: Underlying mechanisms and clinical associations. Clin Genet 2001; 3:165-172.
16. Duijf PH, Vanmolkot KR, Propping P, Friedl W, Krieger E, McKeon F, Dotsch V, Brunner HG, van Bokhoven H. Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. Hum Mol Genet 2002; 11:799-804.
17. Kantaputra P, Hamada T, Kumchai T, McGrath J. Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin ectodermal dysplasia. J Dent Res 2003; 6:433-437.
18. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, Darimont BD, Duijf PH, Van Bokhoven H, McKeon F, Dotsch V. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002; 22:8601-11.
19. Basel D, DePaepe A, Kilpatrick M, Tsipouras P. Split hand foot malformation is associated with a reduced level of Dactylin gene expression. Clin Genet 2000; 4:350-4.
20. Sidow A, Bulotsky MS, Kerrebrock AW, Bronson RT, Daly MJ, Reeve MP, Hawkins TL, Birren BW, Jaenisch R, Lander ES. Serrate2 is disrupted in the mouse limb-development mutant syndactylism. Nature 1997; 389:722-5.
21. Fomenkov A, Huang YP, Topaloglu O, Brechman A, Osada M, Fomenkova T, Yuriditsky E, Trink B, Sidransky D, Ratovitski E. p63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem 2003; 278:23906-14.
22. Wu G, Nomoto S, Hoque MO, DrachevaT, Osada M, Lee CC, Dong SM, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon CS, Ratovitski E, Jen J, Sidransky D, Trink B. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63:2351-7.
23. Weger S, Hammer E, Engstler M. The DNA topoisomerase I binding protein topors as a novel cellular target for SUMO-1 modification: Characterization of domains necessary for subcellular localization and sumoylation. Exp Cell Res 2003; 290:13-27.
24. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E, Sidransky D. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79.
25. Freshney R.I. Culture of animal cells. A manual of basic technique. 4th ed. Wiley-Liss Publications, 2000; (Chapter 11):49-175.
26. Schultz J, Ponting CP, Hofmann K, Bork P. SAM as a protein interaction domain involved in developmental regulation. Protein Sci 1997; 1:249-253.
27. Bernier-Villamor V, Sampson D, Matunis M, Lima C. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 2002; 108:345-356.
28. Johnson E, Gupta A. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 2001; 106:735-744.
29. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002; 108:109-120.
30. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997; 88:97-107.
31. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de The H, Hay RT, Freemont PS. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 1999; 112:381-93.
32. Desterro J, Rodriguez M, Hay R. SUMO-1 modification of IkappaBalpha inhibits NF-κB activation. Mol Cell 1998; 2:233-239.
33. Sternsdorf T, Jensen K, Will H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 1997; 139:1621-1634.
34. Sternsdorf T, Jensen K, Reich B, Will H. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J Biol Chem 1999; 274:12555-12566.
35. Muller S, Dejean A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J Virol 1999; 73:5137-5143.
36. Chakrabarti S, Sood R, Nandi S, Nucifora G. Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. Proc Natl Acad Sci USA 2000; 97:13281-13285.
37. Wood L, Irvin B, Nucifora G, Luce K, Hiebert S. Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci USA 2003; 100:3257-3262.
38. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73α by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 236:316-323.
39. Rodriguez M, Desterro J, Lain S, Midgley C, Lane D, Hay R. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999; 18:6455-6461.
40. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999; 18:6462-71.
41. Boukamp P, Petrussevska R, Breitkreutz D, Hornung J, Markham A, Fusenig N. Normal keratinizatton in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106:761-771.
42. Waltermann A, Kartasheva N, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene2003; 22:5686-5693.
43. Ghioni P, Bolognese F, Duijf P, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 tsoforms: Identification of novel activation and repression domains. Mol Cell Biol 2002; 24:8659-8668.
44. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16.
45. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4:839-43.
46. Akamatsu W, Okano HJ, Osumi N, Inoue T, Nakamura S, Sakakibara S, Miura M, Matsuo N, Darnell RB, Okano H. Mammalian ELAV-like neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc Natl Acad Sci USA 1999; 96:9885-90.
47. Quattrone A, Pascale A, Nogues X, Zhao W, Gusev P, Pacini A, Alkon DL. Posttranscriptional regulation of gene expression in learning by the neuronal ELAV-like mRNA-stabilizing proteins. Proc Natl Acad Sci USA 2001; 98:11668-73.
48. Gantt K, Jain R, Dudek R, Pekala P. HuB localizes to polysomes and alters C/EBP-beta expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2004; 313:619-622.
49. Frejtag W, Zhang Y, Dai R, Anderson M, Mivechi N. Heat shock factor-4 (HSF-4a) represses basal transcription through interaction with TFIIF. J Biol Chem 2001; 276:14685-14694.
50. Zhang Y, Frejtag W, Dai R, Mivechi N. Heat shock factor-4 (HSF-4a) is a repressor of HSF-1 mediated transcription. J Cell Biochem 2001; 82:692-703.
51. Bu L, Jin Y, Shi Y, Chu R, Ban A, Eiberg H, Andres L, Jiang H, Zheng G, Qian M, Cui B, Xia Y, Liu J, Hu L, Zhao G, Hayden MR, Kong X. Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. Nat Genet 2002; 31:276-8.
52. Bernad R, van der Velde H, Fornerod M, Pickersgill H. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol Cell Biol 2004; 6:2373-2384.
53. Forler D, Rabut G, Ciccarelli FD, Herold A, Kocher T, Niggeweg R, Bork P, Ellenberg J, Izaurralde E. RanBP2/Nup358 provides a major binding site for NXF1-p15 dimers at the nuclear pore complex and functions in nuclear mRNA export. Mol Cell Biol 2004; 24:1155-67.
54. Karsenty G. Role of Cbfa1 in osteoblast differentiation and function. Semin Cell Dev Biol 2000; 11:343-346.
55. Aberg T, Wang XP, Kim JH, Yamashiro T, Bei M, Rice R, Ryoo HM, Thesleff I. Runx2 mediates FGF signaling from epithelium to mesenchyme during tooth morphogenesis. Dev Biol 2004; 270:76-93.
56. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 2004; 117:387-98.
57. Sierra O, Cheng S, Loewy A, Charkon-Kachigian N, Towler D. MINT, the Msx2 interacting nuclear matrix target, enhances runx2 - dependent activation of the osteocalcin fibroblast growth factor response element. J Biol Chem 2004; 279:32913-32923.
58. Kuroda K, Han H, Tani S, Tanigaki K, Tun T, Furukawa T, Taniguchi Y, Kurooka H, Hamada Y, Toyokuni S, Honjo T. Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 2003; 18:301-12.
59. Newberry E, Latifi T, Towler D. The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter. Biochemistry 1999; 38:10678-10690.
60. Salghetti S, Muratani M, Wijnen H, Futcher B, Tansey W. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci USA 2000; 97:3118-3123.
61. Salghetti S, Caudy A, Chenoweth J, Tansey W. Regulation of transcriptional activation domain function by ubiquitin. Science 2001; 293:1651-1653.
62. Conaway R, Brower C, Conaway J. Emerging roles of ubiquitin in transcription regulation. Science 2002; 296:1254-1258.
63. Girdwood D, Tatham M, Hay R, SUMO and transcriptional regulation. Semin Cell Dev Biol 2004; 15:201-210.
64. Collavin L, Gostissa M, Avolio F, Secco P, Ronchi A, Santoro C, Del Sal G. Modification of the erythroid transcription factor GATA-1 by SUMO-1. Proc Natl Acad Sci USA 2004; 101:8870-5.
65. Terui Y, Saad N, Jia S, McKeon F, Yuan J. Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J Biol Chem 2004; 279:28257-28265.
66. Lin X, Liang M, Liang Y, Brunicardi F, Feng X. SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem 2003; 278:31043-31048.
67. Gill G. SUMO and ubiquitin in the nucleus: Different functions, similar mechanisms? Curr Opin Genet Dev 2003; 13:108-113.
68. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89:773-9.
69. Garcia-Minaur S, Mavcogiannis LA, Rannan-Eliya SV, Hendry MA, Liston WA, Porteous ME, Wilkie AO. Parietal foramina with cleidocranial dysplasia is caused by mutation in MSX2. Eur J Hum Genet 2003; 11:892-5.
70. Foerst-Potts L, Sadler T. Disruption of Msx-1 and Msx-2 reveals roles for these genes in cranioiacial, eye, and axial development. Dev Dyn 1997; 209:70-84.
71. Jabs EW, Mullet U, Li X, Ma L, Luo W, Haworth IS, Klisak I, Sparkes R, Warman ML, Mulliken JB, et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 1993; 75:443-50.
72. Winograd J, Reilly MP, Roe R, Lutz J, Laughner E, Xu X, Hu L, Asakura T, vander Kolk C, Strandberg JD, Semenza GL. Perinatal lethality and multiple craniofacial malformations in MSX2 transgenic mice. Hum Mol Genet 1997; 6:369-79.
73. Fomenkov A, Zangen R, Huang YP, Osada M, Guo Z, Fomenkov T, Trink B, Sidransky D, Ratovitski EA. RACK1 and Stratifin Target DeltaNp63alpha for a Proteasome Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage. Cell Cycle 2004; 3:1285-95.